Akari Therapeutics PLC logo

Akari Therapeutics PLC

$ 0.64 +0.006 (+0.95%) 03:59 PM EST
P/E:
At Loss
P/B:
4.57
Market Cap:
$ 37.98M
Enterprise V:
$ 29.48M
Volume:
111.85K
Avg Vol (2M):
95.18K
Also Trade In:
Volume:
111.85K
Market Cap $:
37.98M
PE Ratio:
At Loss
Avg Vol (2-Month):
95.18K
Enterprise Value $:
29.48M
PB Ratio:
4.57
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.73
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 53.17
9-Day RSI 33.29
14-Day RSI 29.9
6-1 Month Momentum % -3.81
12-1 Month Momentum % -33.24

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.73
Quick Ratio 3.73
Cash Ratio 2.68

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -44.4
Name Current Vs Industry Vs History
ROE % -221.95
ROA % -145.87
ROIC % -6616.91
ROC (Joel Greenblatt) % -11791.67
ROCE % -225.63

Financials (Next Earnings Date:2022-12-02 Est.)

AKTX's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:AKTX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -0.349
Beta 1.08
Volatility % 51.68
14-Day RSI 29.9
14-Day ATR ($) 0.075539
20-Day SMA ($) 0.73189
12-1 Month Momentum % -33.24
52-Week Range ($) 0.504 - 1.8294
Shares Outstanding (Mil) 59.35

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Akari Therapeutics PLC Filings

Document Form Filing Date
No Filing Data

Akari Therapeutics PLC Analysis

Share your research

Headlines

See More
No news.